Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06808932 · ClinicalTrials.gov registry record · Phase 1
VK4-116 Phase I Study With Food-Effect
A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Not yet
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT06808932 is a Phase 1 study that has not yet begun recruiting, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 48 participants.
The verdict
NCT06808932, a Phase 1 study, has not yet begun recruiting, sponsored by National Institute on Drug Abuse (NIDA).
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This first-in-human, randomized, double-blind, placebo-controlled, single ascending dose (SAD), phase I study is designed to assess the safety, tolerability and pharmacokinetics of VK4-116 in healthy volunteers in fasted and fed state.
Interventions
- DRUG Placebo
- DRUG VK4-116
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2027-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06808932
The ClinicalTrials.gov registry entry for NCT06808932 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06808932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06808932 about?
NCT06808932 is a clinical study titled "VK4-116 Phase I Study With Food-Effect". This first-in-human, randomized, double-blind, placebo-controlled, single ascending dose (SAD), phase I study is designed to assess the safety, tolerability and pharmacokinetics of VK4-116 in healthy volunteers in fasted and fed state.
What is the current status of trial NCT06808932?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2026-08-01. Estimated completion is 2027-08-30.
What interventions are being tested in trial NCT06808932?
The interventions under investigation include: Placebo (DRUG), VK4-116 (DRUG).
Who is sponsoring clinical trial NCT06808932?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.